Wanbury Reports Robust H1FY26 Results with 216.6% PAT Growth
Wanbury Limited announced robust financial results for Q2 and H1 FY26. H1 FY26 highlights include revenue growth of 10.60% to ₹323.20 crore, EBITDA increase of 51.30% to ₹50.80 crore, and PAT surge of 216.60% to ₹28.70 crore. Q2 FY26 saw revenue at ₹160.10 crore, EBITDA up 20.10% YoY, and PAT growth of 89.30% to ₹15.20 crore. Key growth drivers include volume growth, cost efficiencies, yield enhancement, and lower finance costs. The company implemented strategic initiatives like digital transformation and new product launches. Management remains focused on sustaining efficiencies, expanding capacities, and strengthening its global market position.
*this image is generated using AI for illustrative purposes only.
Wanbury Limited , a prominent pharmaceutical company, has announced strong financial results for the second quarter and first half of fiscal year 2026, showcasing significant growth across key metrics.
Financial Highlights
The company reported impressive gains for H1FY26:
| Particulars | H1 FY26 | H1 FY25 | Y-o-Y Growth |
|---|---|---|---|
| Revenue from Operations | 323.20 | 292.30 | 10.60% |
| EBITDA | 50.80 | 33.60 | 51.30% |
| EBITDA Margin | 15.70% | 11.40% | 430 bps |
| PAT | 28.70 | 9.10 | 216.60% |
| PAT Margin | 8.90% | 3.10% | 578 bps |
Q2FY26 Performance
For the second quarter of FY26, Wanbury reported:
- Revenue from Operations: 160.10 crore
- EBITDA: 26.00 crore, up 20.10% YoY
- EBITDA Margin: 16.20%, an improvement of 292 bps YoY
- PAT: 15.20 crore, showing a significant growth of 89.30% YoY
- PAT Margin: 9.50%, up from 4.90% in Q2FY25
Key Growth Drivers
The company's robust performance can be attributed to several factors:
- Volume Growth: Increased sales volumes contributed to the revenue uptick.
- Cost Efficiencies: Improved operational efficiency and cost management.
- Product Yield Enhancement: Better production yields boosted profitability.
- Lower Finance Costs: Reduced financial expenses positively impacted the bottom line.
- Procurement Efficiencies: Optimized sourcing for raw materials and supplies.
- Field Force Productivity: Enhanced sales team performance and promotional activities.
Strategic Initiatives
Wanbury has implemented several strategic initiatives to drive growth:
- Digital Transformation: The company has implemented SAP S/4HANA Private Cloud, enhancing operational agility and data-driven decision-making.
- New Product Introduction: Successfully launched a liposomal iron supplement.
- Brand Promotion: Increased focus on various brand promotional activities.
- Training Programs: Targeted training to improve sales force productivity.
Management Commentary
Mr. K S Rayana, Director of Wanbury Ltd., commented on the results: "Q2 continued our robust growth trajectory, with PAT of 15.20 crore in Q2 FY26, a 89.30% increase compared to 8.00 crore in Q2 FY25. This improvement was driven by cost efficiencies, improved product yield, and lower finance costs."
He further added, "Our efforts are aimed at strengthening Wanbury's position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders."
Future Outlook
Wanbury remains focused on:
- Sustaining operational efficiencies
- Expanding production capacities
- Maintaining high-quality standards
- Introducing new products
- Strengthening its position in the global pharmaceutical market
The company's strong H1FY26 performance, coupled with its strategic initiatives, positions Wanbury for continued growth in the pharmaceutical sector.
Note: All financial figures are in Indian Rupees (₹) crore.
Historical Stock Returns for Wanbury
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.08% | -1.65% | -2.95% | -5.03% | +17.43% | +187.49% |
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
